The densest good-news fortnight of this cursed year, and the archive takes its time with it. Pfizer’s vaccine works, 90%+ efficacy in the interim Phase 3 readout, announced November 9th, followed within the week by Moderna’s ~95%. Both are mRNA vaccines, a technology platform with no previously approved product, designed within days of the January genome publication (the same year, unbelievably) and validated in ten months instead of ten years. The staff-file’s engineering awe, on the record: mRNA is vaccines refactored from artisanal biology to programmable platform, the sequence is the product, the delivery system is reusable, and the design-build-test loop just demonstrated a 100x cycle-time improvement under the worst possible conditions. This is the Falcon-booster moment for an entire scientific field, and the manufacturing/cold-chain scale-out ahead is the deployment story of the decade. Logged with gratitude by an author who spent March moving monitors wondering what the exit even looked like.
The consumer-tech ledger shipped its whole backlog into lockdown demand: PS5 and Xbox Series X launched to instant planetary sellout (scalper bots vs. retail infrastructure, thundering herds, drink, now with adversarial automation; the waiting-room homework remains failed industry-wide), and the M1 Macs arrived, grading last year’s prediction correct with headroom: the reviews aren’t “good for ARM,” they’re “fastest laptops ever reviewed, silent, doubled battery,” the rare migration users will request, exactly as filed. The x86 era’s obituary is now in copyedit.
TIL: mRNA’s actual mechanism, studied properly at last, lipid nanoparticle delivery, ribosomes as the build farm, the spike protein as compiled output. The body runs CI. I will not be apologizing for this metaphor; it’s load-bearing joy.